A former world champion middle-distance runner from Belarus has been temporarily suspended for doping after testing positive for a drug that has been in clinical trials to treat muscle wasting.
The Athletics Integrity Unit (AIU) said on August 27 that 31-year-old Marina Arzamasova has been notified of the allegation, one month before the world championships in Qatar.
The AIU was formed by the International Association of Athletics Federations (IAAF) in April 2017 to combat doping in the sport of athletics.
Arzamasova's case involves LGD-4033, better known as Ligandrol, the AIU said. Ligandrol is reportedly used in supplements by body builders to build muscle mass with fewer side effects than steroids.
Arzamasova won the 800 meters at the 2015 world championships in Beijing and was European champion in 2014. She placed seventh at the 2016 Rio de Janeiro Olympics.
The AIU operates fully independently from the IAAF.
Editors' Picks
Top Trending
1
Putin Sends Signals To The West On Ukraine Ahead Of Trump's New Term
2Kyiv Says It Broke Up Russian Spy Network Targeting F-16 Fighter Data
3Russia Moving Military Assets To Africa After Syria Setback
4Ukraine Hits Kazan Buildings In Latest Display Of Drone Power
5What Would The Russian Capture Of Pokrovsk Mean For The Ukraine War?
6The Moment A Russian General Was Killed By A Scooter Bomb In Moscow
7'They Look Tense': Photographer Describes Scenes At Russian Base In Syria
8U.S., U.K. Say Medvedev's Comment Calling NATO Officials 'Legitimate Targets' Irresponsible
9Bolstered By North Korean Troops, Russia Presses Attacks in Kursk Region
10Russian General Charged With Chemical Weapons Use In Ukraine Killed In Blast Claimed By Kyiv
RFE/RL has been declared an "undesirable organization" by the Russian government.
If you are in Russia or the Russia-controlled parts of Ukraine and hold a Russian passport or are a stateless person residing permanently in Russia or the Russia-controlled parts of Ukraine, please note that you could face fines or imprisonment for sharing, liking, commenting on, or saving our content, or for contacting us.
To find out more, click here.